Taiwanese biopharmaceutical company Golden Biotechnology Corp. on Wednesday released positive interim unblinded data from the Phase 2 clinical trial of its oral investigational new drug for COVID-19 Antroquinonol, and announced it plans to apply for Emergency Use Authorization (EUA) in the United States in April.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
Voting begins for Taiwan's opposition KMT chairperson
10/18/2025 12:22 PM - Society
Taiwan headline news
10/18/2025 11:23 AM - Society
Magnitude 5.3 earthquake shakes eastern Taiwan
10/18/2025 10:25 AM - Society
Taroko National Park closes due to barrier lake overflow alert
10/17/2025 11:11 PM - Society